UPF CRG - Sant Pau_AD synaptic

Search for synaptic biomarkers of Alzheimer’s disease

  • Organism: Homo sapiens
  • Instrument: QTRAP 5500
  • SpikeIn: Yes
  • Keywords: Alzheimer’s disease, cerebrospinal fluid, synapse, biomarkers, selected reaction monitoring
Abstract
As synapse degeneration is an early event in Alzheimer’s disease (AD) pathophysiology, a biofluid marker of synapse loss in living patients could be a surrogate marker of disease prognosis and therefore would be an excellent addition to the AD biomarker arsenal. With direct access to the brain interstitial fluid, the cerebrospinal fluid (CSF) is a potential source of synapse-derived proteins that could be potential biomarkers of underlying synapse degeneration. The aim of this study was to identify, verify and evaluate a set of synaptic proteins as surrogate CSF markers of underlying synapse loss in AD patients. In the Discovery Stage, we combined high-throughput shotgun proteomics of the CSF with an exhaustive search of the literature and public databases for proteomic studies of the CSF and synapse. A thorough characterization of the synaptic component of the CSF identified 210 synaptic proteins that are detectable in human CSF. We selected an initial panel of 22 candidate biomarkers for evaluation. In the Verification Stage, 12 proteins were discarded due to poor detection by targeted mass spectrometry (Selected Reaction Monitoring, SRM). We confirmed the expression of the remaining 10 proteins either directly at (Calsynytenin-1, GluR2, GluR4, Neurexins 2A and 3A, Neuroligin-2, Syntaxin-1B, Thy-1 and Vamp-2), or surrounding (Tenascin-R), the human synapse using Array Tomography microscopy and biochemical fractionation methods. We quantified the synaptic panel by SRM in CSF samples from 2 independent clinical cohorts of cognitively normal controls and all clinical stages of AD (n=140). A set of the panel proteins demonstrated a non-linear profile distinct to that of existing biomarkers whereby the CSF levels were decreased at the earliest preclinical stage of AD, reflecting reduced synaptic density in these asymptomatic individuals and elevated at later symptomatic stages when neurodegeneration is widespread. In conclusion, we have identified a set of novel synapse-specific proteins that could have clinical value for assessing disease progression in individuals at-risk for AD and potentially in other neurological disorders characterized by early synapse loss.
Created on 12/20/18, 10:41 AM
Clustergrammer Heatmap
Flag FileDownloadCreatedProteinsPeptidesPrecursorsTransitionsReplicates
180913_OBAL_picked-rep1_2018-12-20_10-43-34.sky.zip (10 MB)2018-12-2015224420638
160616_OBAL_95_samples_quant_high_quality_2018-12-20_10-50-47.sky.zip (77 MB)2018-12-2013173415895
160616_OBAL_95_samples_quant_2018-12-20_10-50-06.sky.zip (77 MB)2018-12-2015224420695
170208_OBAL_Samples_refined_2018-12-20_10-37-30.sky.zip (39 MB)2018-12-2015224421096